Thank you for subscribing!
Next Investors Archived May 21, 2018
BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.
Next Investors Archived May 17, 2018
Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.
Finfeed Archived May 16, 2018
Rhythm Biosciences (ASX:RHY) has today announced that coverage of its granted European patent (EP2829881) has been confirmed in 13 jurisdictions.
Finfeed Archived May 14, 2018
Rhythm Biosciences (ASX:RHY) has completed the first phase development of two new antibody reagents.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 10, 2018
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has today announced its most significant clinical milestone to date — the highly encouraging results of its PTX-200 Phase 1b Breast Cancer trial.
Finfeed Archived Mar 29, 2018
ASX small-cap Prescient Therapeutics (PTX) is bringing two novel cancer drugs to the table; PTX-200 to treat breast cancer, ovarian cancer and acute myeloid leukaemia (AML), and PTX-100 to treat a range of solid and blood cancers.
Finfeed Archived Mar 15, 2018
PharmAust (ASX:PAA), a clinical-stage oncology company, has revealed its new collaboration with Dr Doug Fairlie, a leading cancer researcher based at Victoria’s prestigious Olivia Newton-John Cancer Research Institute (ONJCRI).
Next Investors Archived Mar 13, 2018
This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.
Finfeed Archived Mar 06, 2018
BARD1 Life Sciences (ASX:BD1) has announced additional positive results from its BARD1-Ovarian test, indicating that the test returned 89% sensitivity and 82% specificity.
Join Our Mailing List
